Joseph Payne; President, Chief Executive Officer, Director; Arcturus Therapeutics Holdings Inc Andrew Sassine; Chief Financial Officer, Director; Arcturus Therapeutics Holdings Inc Padmanabh ...

Arcturus Therapeutics Holdings Inc. (ARCT) reported a wider-than-expected loss for the fourth quarter of 2024, with earnings per share (EPS) of -$1.11, missing the forecast of -$0.19. The company ...

Canaccord analyst Whitney Ijem lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $68 from $74 and keeps a Buy rating on the shares. The firm said its 4Q24 earnings report had ...

H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $60 from $63 and keeps a Buy rating on the shares. Arcturus on Thursday announced that interim ...

Analysts' ratings for Arcturus Therapeutics ARCT over the last quarter vary from bullish to bearish, as provided by 8 analysts. The table below offers a condensed view of their recent ratings ...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and ...

HC Wainwright reiterated a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research note on Friday, February 14th. BTIG Research initiated coverage on shares ...

Good day, everyone, and welcome to today's Arcturus Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later ...

Meanwhile Arcturus, a San Diego biotech working with messenger RNA (mRNA) therapies said it is working with Duke-NUS Medical School (Duke-NUS) to develop a coronavirus vaccine for Singapore.

This page features the latest Arcturus Therapeutics Holdings Inc share stories and breaking news. Assess the latest information about the Arcturus Therapeutics Holdings Inc stock. Our team of expert ...